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Abstract 
The novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has 
leaded to a global infection and a pandemic afterwards. This pandemic is one 
of the greatest global challenges for the health system. In this review, the 
immunologic basis of the human body response after infection with SARS-
CoV2 has been reviewed with discussions on both innate and adaptive 
immunity. Due to the relatively short time after appearance of the problem, the 
currently available evidence exclusively dealing with SARS-CoV2 and the 
disease, coronavirus diseases 2019 (COVID-19) are scant; especially in the 
field of cellular and molecular medicine; however, previous studies especially 
focusing on SARS-CoV and MERS are available. At the final part of the 
manuscript, involvement of the main human organs with COVID-19 is briefed. 
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Introduction 
Coronavirus disease 2019 (COVID-19) has 
appeared since December, 2019, is caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV2) (1, 2). This pandemic outbreak has challenged 
not only the global health care system but also the 
majority of life aspects all over the world. 
How could human being fix the problem? An 
exact and vivid understanding of the viral effects on the 
body and the human responses would be undoubtedly 
among the first steps of finding a solution.  
How does the human body interact with the 
SARS-CoV2? Here we discuss the response of the 
immune system towards SARS-CoV2 infection. In 
general, two types of intermingled immune responses 
are reported to be involved during any viral infection 
including, SARS-CoV2 infection; innate and adaptive 
immunity. 
We first discuss the innate immune response and 
then the adaptive one. Throughout the text, the author 
should remember that due to the novelty of SARS-
CoV2 in the world, many of the studies, both in vivo 
and in vitro, are related to the two other members of 
the Coronaviridae family, SARS-CoV and Middle 
East respiratory syndrome (MERS-CoV), which 
caused known epidemics in the world throughout two 
recent decades. However, there are studies directly 
related to SARS-CoV2. 
The study proposal was assessed and approved 
by Research Ethics Committee, Tehran University of 
Medical Sciences, Tehran, Iran; coded: 
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Mechanism of viral entry to the human body 
SARS-CoV2 binds to Angiotensin converting 
enzyme 2 (ACE2) through spike (S) glycoproteins and 
enters to the host cells by endocytosis. S glycoprotein 
is composed of two components, S1 and S2, the first 
one is responsible for attachment of the virus to ACE2 
and the latter induces fusion of viral body with the 
target cell membrane (3). In SARS-CoV2, a furin 
cleavage site is existed between S1 and S2. This area 
is unique to SARS-CoV2 and is not presented in earlier 
pathogenic members of the coronaviridae family (3). 
In addition, priming of S protein by a serine protease, 
named TMPRSS2, is obligatory for entrance of the 
virus into target cells (4). ACE2 presents in many 
tissues; however, surface protein expression is more 
restricted to lung alveolar epithelial cells and 
enterocytes of small intestine (5, 6); viral attachment to 
ACE2 would ultimately result in respiratory and 
gastrointestinal symptoms. On the other hand, ACE2 
inactivates angiotensin II and functions as a 
vasodilator. In a controversial finding in mice models, 
ACE2 could protect mice from acute respiratory 
distress syndrome (ARDS) (7). Similar protective roles 
for ACE2 were proposed for COVID-19 indeed (8). 
Innate immune responses against Coronaviruses 
Viruses could invade to different types of 
immune and non-immune cells in the upper and the 
lower respiratory tract. Pattern recognition receptors 
(PRRs) in cytosol or endosomal membranes of infected 
cells sense viral nucleic acids and initiate signaling 
pathways; a gate keeping process that mainly results in 
production of type 1 interferons (IFN-α and β) (9).  
Retinoid-inducible gene (RIG) like receptors 
(RLRs) are the main members of PRRs; they recognize 
cytosolic viral RNA and trigger antiviral responses. 
RIG1 detects RNA molecules with triphosphate groups 
at 5΄ end. On the other hand, melanoma differentiation-
associated gene 5 (MDA5) identifies longer temporary 
viral double stranded RNAs (dsRNAs) formed in 
cytosol during replication of RNA viruses. TLR3 and 
TLR7, which are endosomal membrane receptors, 
could be involved in recognition of dsRNA, which are 
produced throughout viral replication, and single 
stranded RNA (ssRNA) of coronaviruses, respectively. 
Following recognition of viral RNA by these PRRs, 
other adaptor molecules will be recruited; finally 
resulting in transcription of nuclear factor κB (NF-κB) 
and interferon regulatory protein 3 (IRF3) which in 
turn induce production of pro-inflammatory cytokines 
and type I interferons (9-11), as a protective innate 
immune response in initial phase of viral infection. 
Pneumocyte type II as the main target of SARS-
CoV2 has essential role in innate immunity by 
providing barrier effect and sensing the pathogen and 
inducing production of anti-viral cytokines (12, 13).  
Uptake of SARS-CoV by dendritic cells (DCs) 
has been shown by electron microscopy in vitro. It 
seems that the process is not mediated by ACE2 and 
other molecules involved in virus entry to cells. 
Coronaviruses are replicated inside DCs; although this 
replication seems to be incomplete. Replication of 
virus in immature DCs, does not induce maturation or 
apoptosis of these cells. SARS-CoV infected DCs 
produce lower amount of anti-viral cytokines e.g. IFNs 
and IL-12, while moderate amount of tumor necrosis 
factor α (TNF- α) and IL-6 and higher amount of 
chemokines (14). On the other hand, Cheung et al 
confirmed that monocyte derived macrophages can 
fetch SARS-CoV in vitro. Transcription of virus genes, 
and thereafter synthesis of viral proteins begin inside 
the macrophages; however, this process halts and 
complete virus is not produced finally. At the same 
time, production of chemokines, including interferon 
gamma-induced protein 10 (IP-10) and monocyte 
chemoattractant protein 1 (MCP1), was upregulated 
while synthesis of IFN-β was decreased (15). Based on 
the above evidences, SARS-CoV triggers chemokine 
production while prevents interferon production; this 
leads to more accumulation and recruitment of the 
immune cells in situ. 
Plasmacytoid dendritic cells are the main source 
of interferon type 1 (IFN-α and β), in contrast to 
conventional dendritic cells which are not able to 
produce large amount of type 1 interferons upon 
contamination with SARS-CoV (16, 17). These 
interferons induce different interferon stimulated genes 
(ISGs) which in turn ensue to anti-proliferative and 
antiviral state (16). 
Virus Evade mechanisms from innate immunity 
The initial response against viruses is mediated by 
production of type 1 interferons; meanwhile, previous 
studies have shown that coronaviruses could bypass 
both production and function of these interferons by at 
least three IFN-I antagonists, including open reading 
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frame (ORF)3b, ORF6 and nucleocapsid proteins (N 
proteins) (18). In addition, ORF6 has the ability to 
antagonize transportation of STAT1 to the nucleus and 
in this way, inhibits host antiviral responses (19). It 
was shown that coronaviruses escape from being 
recognized by cytosolic PRRs through creation of 
double membrane vesicles, where replication of virus 
happens (20). In addition, viral nucleocapsid proteins 
can interfere with ubiquitination and therefore 
activation of RIG1 (21). In spite of all these diverse 
evasion mechanisms of SARS-CoV, plasmacytoid 
dendritic cells as the main sources of type 1 interferons 
provide anti-viral immunity (17, 22-24).  
Adaptive immune responses against Coronaviruses 
For long-lasting immunity, adaptive immune 
responses are mandatory. Specific T and B-
lymphocytes mediate acquired immunity. Like other 
viral infections, cytotoxic T lymphocytes (CTLs) seem 
to play an important role in elimination of infected 
cells. Zhou et al. identified a decameric epitope of S 
protein which could be presented by HLA-A*0201 and 
stimulate IFN-γ production by CTLs (25). A delayed 
and disturbed T cell response has been reported in 
SARS-CoV infections, which could be related to 
disrupted competency of DCs in processing and 
presenting antigens to T lymphocytes. In addition, 
abundant IFN type I production could induce apoptosis 
of T cells (26). Peng et al. demonstrated persistence of 
memory CD4+ and CD8+ T cells two years after 
recovery of SARS-CoV infected patients. These 
memory cells were specific for a nucleocapsid protein 
epitope. The authors suggested that some epitopes of N 
proteins could be presented more frequently by antigen 
presenting cells and thus and consequently are able to 
induce more robust T cell responses. However, these 
epitopes are not necessarily the ones that stimulate 
strong B cell responses (27). Also, Zhao et al. 
emphasized on importance of T cell responses in 
clearance of SARS-CoV and confirmed that 
insufficient T cell responses could play a significant 
role in pathogenesis of ARDS (28). 
Antibodies as the main product of B 
lymphocytes play an important role in neutralizing 
corona viruses; however, this neutralizing role is not 
inclusive for all human antibodies produced in 
response to the virus; in other words, a specific profile 
of produced antibodies could work as neutralizing 
agents against the virus. The role of CD4+ T cells is 
essential for creation of these antibodies (29).  
Antibodies presented in convalescent plasma of 
COVID-19 patients are able to decrease the titer of 
virus in critically ill patients, even to undetectable 
amounts. This seems to be related to the presence of 
neutralizing antibodies in plasma of recovered patients 
(30). These beneficial effects were reported previously 
in studies regarding SARS-CoV and MERS-CoV (31-
34). Neutralizing antibodies need to act against 
nucleocapsid and spike proteins. These antibodies 
begin to be produced nearly ten days after symptom 
onset and are composed of IgM (mainly in the initial 
phase); after a while, these antibodies are 
predominantly converted to IgG (35, 36).  
The antibodies work by several different 
mechanisms. Some of them can function as 
neutralizing antibodies which prevent attachment of 
the virus to its receptor on the target tissues; however, 
some others can opsonize the virus and facilitate its 
elimination by phagocytes, induce the recruitment of 
other immune cells or collaborate in deposition and 
activation of complement components (37). 
Whichever of these mechanisms is involved in 
omitting the virus, it should be considered that 
antibody production requires the assistance of CD4+ 
helper T cells.  
Host HLA type play an important role in 
presenting viral protein antigens and shaping the 
immune responses (38). Recognition of immune-
dominant epitopes of SARS-CoV2 by techniques such 
as epitope mapping seems to be an important part of 
vaccine development (39, 40). 
Role of cytokines in pathogenesis of COVID-19  
Large amount of cytokines are produced and 
released by different types of infiltrated immune cells 
in respiratory tract upon viral infection. Huang et al. 
reported higher amount of Interleukin (IL)2, IL7, IL10, 
Granulocyte-colony stimulating factor (GCSF), IP10, 
MCP1, macrophage inflammatory protein 1 (MIP1) 
and TNF-α in Covid-19 patients who were admitted to 
ICU compared to non-admitted ones (41).  
Although these cytokines are released initially 
as a defense response, uncontrolled production and 
release of the cytokines, which is known as cytokine 
storm, finally lead to a severe proinflammatory 
condition in critically ill patients (38).  
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A summary of COVID-19 main organ involvement  
 
Pulmonary involvement  
The pathologic findings in lungs during 
COVID-19 are much similar to SARS and MERS and 
include a combination of the following findings (42-
44): 
 pulmonary edema and hyaline membrane 
formation (early stages of ARDS) 
 proliferation and enlargement of pneumocytes 
associated with amphophilic granular pattern in the 
cytoplasm and enlarged nucleoli indicating cytopathic 
pneumocyte changes which finally lead to 
desquamation of pneumocytes into the alveoli (later 
stages of ARDS)  
 diffuse and bilateral alveolar injury and fibroid 
cellular exudates in alveoli with accumulation of 
mononuclear inflammatory infiltrates, dominated by 
lymphocytes added with myriads of type II 
pneumocytes and clustering of CD68-positive 
macrophages in the alveolar spaces 
 interstitial infiltration of mononuclear cells 
especially lymphocytes (mostly CD3-positive and 
CD20-negative) 
Cardiovascular involvement  
The underlying inflammatory nature of 
COVID-19 has direct detrimental effects on the 
cardiovascular system; not only because of the immune 
system disturbances and inflammatory responses but 
also due to the abundancy of ACE2 in the 
cardiovascular system; on the other hand, underlying 
cardiovascular disease is an important mortality risk 
factor in COVID-19 patients (45). Add to the above the 
finding that myocardial damage due to SARS-CoV2 is 
among the challenging pathologic features of the 
disease; which could be seriously associated with 
widespread damage to the myocardial tissue. In the 
latter patients, often the serum levels of "high-
sensitivity cardiac troponin I" and "Creatine-Kinase-
MB: CK-MB" surged dramatically. Even though, a 
minority of COVID-19 patients may be involved with 
cardiovascular problems as their presenting illness. 
However, in COVID-19 patients with underlying heart 
failure, hypertension, or myocardial infarction, ACE 
inhibitors should not be abstained (46-48).  
Renal involvement  
ACE2 is expressed on kidney cells and acute 
kidney injury was reported as a comorbidity in 
COVID-19. Despite previous studies that have not 
been able to show the presence and replication of 
SARS-CoV directly in the kidney cells (49), novel 
SARS-CoV2 has been found in kidney tubular cells 
and was able to induce acute tubular damage (50). In 
addition, kidney could be involved during cytokine 
storm. Dialysis in patients with chronic kidney disease 
could demonstrate beneficial effects in reduction of 
lung inflammation (51). In a recent study, it was shown 
that COVID-19 is not a provoking factor for acute 
kidney injury (52); however, other study contrary 
indicated worsening of acute kidney injury during 
hospitalization in Covid-19 admitted patients (53) .  
Gastrointestinal involvement  
Gastrointestinal symptoms were reported in 
COVID-19 cases including anorexia, nausea, vomiting 
and diarrhea (54, 55). SARS-CoV2 RNA was reported 
in stool specimens; Also ACE2 was highly expressed 
on the surface of enterocytes (5). These evidences 
implicate active replication of virus in gastrointestinal 
epithelial cells (56).  
Neurological involvement  
ACE2 is expressed on the surface of neurons 
and glial cells. Two ways were proposed for CNS 
involvement with SARS-CoV2; first by systemic 
distribution of virus and the second one, by local 
transmission through ethmoidal bone. The circulatory 
virus can attach to ACE2 on the surface of capillary 
endothelial cells and enter the cells. Following viral 
egression, endothelial cells would be damaged and this 
causes accessibility of virus to the brain which contain 
numerous neurons with ACE2. The direct arrival of 
virus through cribriform plate might result in disturbed 
sense of smell (57). Different symptoms of central and 
also, peripheral nervous system have been reported in 
COVID-19 patients (58). Furthermore it was reported 
that SARS-CoV2 has the potential to engage 
respiratory center in brain stem which may lead to 
respiratory failure in patients with COVID-19 (59). 
Conclusion   
Overall, corona virus infections could involve 
both innate and adaptive immune responses. While in 
initial phases of the infection, production of type 1 
interferons play more important role in defense against 
the virus, long-lasting immunity needs the activation of 
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adaptive immunity, through production of neutralizing 
antibodies by B lymphocytes with the assistance of T 
cells. Providing this type of immunity is essential in 
vaccine development. 
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